Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 – This Highly Lucrative Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion – ResearchMoz

VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)

Albany NY (February 26, 2013) (CULRAV.ORG) -

 

New Report Added in ResearchMoz Reports Database Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion Researchmoz

To Browse Full TOC, Tables & Figures visit: http://www.researchmoz.us/monoclonal-antibodies-market-in-rheumatoid-arthritis-to-2018-market-characterized-by-large-and-diversified-pipeline-and-low-threat-of-biosimilar-sales-erosion-report.html

GBI Research, the leading business intelligence provider, has released its latest research, Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion. The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the global top 20 best-selling drugs. The unique density of monoclonal antibodies that are approved for this indication, significant market exclusivity expiries in the forecast period and yet more monoclonal antibodies in development will change the dynamics in and this highly lucrative market in the forecast period until 2018.
Scope
  • The current therapeutic environment in the treatment of RA across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.
  • Analysis of the competitive environment for monoclonal antibodies with strong data and evidence-based profiling of marketed products, including comparative benchmarking and assessment of efficacy and safety profiles as well as differentiating product features.
  • A detailed pipeline analysis for monoclonal antibodies in rheumatoid arthritis including individual product profiles, a comparative efficacy and safety profile heat map analysis of the most promising pipeline products as well as analyses on the distribution of molecule types across the RA developmental pipeline, the molecular targets of pipeline mAbs and the developmental program types. In addition, detailed analyses of the clinical trial failure rates, the clinical trial durations by phase and clinical trial sizes by participant numbers are provided.
  • Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.
  • Market forecasts across the US, the top five countries in Europe (EU5) Germany, France, the UK, Italy, and Spainas well as Japan. The multiple scenario forecasts take a range of factors that are likely to vary into account and provide a clear perspective on the level of the potential degree of variance in the market sizes.
  • Key market drivers and barriers
  • the major deals that have taken place in the monoclonal antibodies market in rheumatoid arthritis in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and molecular targets is also provided.
Reasons to buy
  • Understand the competitive environment for monoclonal antibodies
  • Develop key strategic repositioning initiatives by studying the repositioning trends and strategies of current competitors
  • Understand the clinical and commercial impact of the growing diversification of the molecular targets of monoclonal antibodies in the pipeline and identify potential first-in-class products
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the RA market in the forecast period
  • Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for monoclonal antibodies in RA
  • Use key benchmark data to forecast costs of developmental programs for monoclonal antibodies in RA by using proprietary clinical trial size and duration analyses
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
  • Use proprietary data analyses to assess the market value of pipeline molecules for in-licensing and out-licensing opportunities

Related Reports:

MRI Systems Market to 2018 @ http://www.researchmoz.us/mri-systems-market-to-2018-technological-advancements-increasing-number-of-applications-and-advent-of-mri-compatible-pacemakers-to-drive-future-growth-report.html

The report provides the market landscape, competitive landscape and market trends on the three MRI systems market segments: low-field MRI systems, mid-field MRI systems and high-field MRI systems segments. The report provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape and gives a detailed analysis of the pipeline products in each segment. In addition, it reviews details regarding important merger and acquisition deals that have taken place in the global MRI systems market.

Acquired Orphan Blood Diseases Therapeutics Market to 2019 : @ http://www.researchmoz.us/acquired-orphan-blood-diseases-therapeutics-market-to-2019-search-for-disease-modifying-drugs-central-to-unlocking-premium-pricing-potential-report.html

The report provides insights into the up-and-coming trends of a portion of the acquired orphan blood disorder pharmaceutical market by examining Idiopathic Thrombocytopenic Purpura (ITP), Myelodysplastic Syndrome (MDS), Myelofibrosis (MF), Paroxysmal Nocturnal Hemoglobinuria (PNH) and Polycythemia Vera (PV) in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan.

The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.

About Us

 ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

 

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Email: sales@researchmoz.com  

http://www.researchmoz.us/

VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)
VN:F [1.9.22_1171]
Rating: +1 (from 1 vote)
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - This Highly Lucrative Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion - ResearchMoz, 5.0 out of 5 based on 1 rating

Nish Kindle
Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning. ResearchMoz is the one stop online destination to find and buy market research reports.

Comments are closed.